Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended June 30, 2000 (and period from inception on February 14, 2000).
Business Overview: Curis, Inc. was incorporated on February 14, 2000, as a shell vehicle to effect a merger with Creative BioMolecules, Inc., Ontogeny, Inc., and Reprogenesis, Inc. The company operates in the regenerative medicine field, focusing on protein factors, cell therapies, tissue engineering, and small molecules.
Key Financial Metrics
| Metric | Value (Period from Inception to June 30, 2000) |
|---|---|
| Total Assets | $30 |
| Cash and Cash Equivalents | $30 |
| Total Liabilities | $0 |
| Stockholders' Equity | $30 |
| Revenues | $0 |
| Net Loss | $0 |
| Net Cash Provided by Financing Activities | $30 |
| Shares Outstanding (as of Aug 7, 2000) | 25,944,393 |
Note: The financial statements reflect the shell company status prior to the closing of the merger. No operating expenses or revenues were recorded for Curis, Inc. during this period.
Material Changes and Subsequent Events
The most significant event disclosed is a Subsequent Event occurring on July 31, 2000, following the reporting period:
- Merger Completion: Curis, Inc. merged with Creative BioMolecules, Ontogeny, and Reprogenesis. Curis is the surviving entity.
- Accounting Treatment: The merger is accounted for as a purchase of Ontogeny and Reprogenesis by Creative (the accounting acquirer). Creative's historical financial statements become the historical statements of the combined company.
- Ownership Structure: Post-merger ownership is approximately 43% former Creative stockholders, 38% former Ontogeny stockholders, and 19% former Reprogenesis stockholders.
- Estimated Purchase Price: Based on Creative's stock price of $8.357, the estimated purchase price for Ontogeny is $303.6 million and for Reprogenesis is $154.8 million.
- Intangible Assets: Significant portions of the purchase price are allocated to In-Process Research and Development (IPR&D) ($186.2M for Ontogeny; $108.6M for Reprogenesis) and goodwill ($80.4M for Ontogeny; $42.9M for Reprogenesis).
Guidance, Outlook, and Risks
Liquidity and Capital Resources:
- As of June 30, 2000, the shell company held only $30 in cash.
- Post-merger capital resources will equal the combined cash and marketable securities of the three predecessor companies.
- Outlook: Management anticipates existing capital resources will fund operations through the end of 2001.
Risks and Contingencies:
- IPR&D Expense: The fair value of acquired IPR&D ($294.8 million total) will be recorded as an expense in the September 30, 2000 financial statements because the technology has no alternative use if development fails.
- Regulatory Risk: Technologies face significant risks regarding FDA approval. Failure to achieve approval or the need for alternate indications subjects the company to further clinical trial risks.
- Market Risk: No market risks requiring disclosure were identified as of June 30, 2000.
Investor Verification Checklist
- Merger Closing Date: Verify the final closing date of July 31, 2000, and the exact number of shares issued to former Ontogeny and Reprogenesis shareholders.
- Combined Cash Position: Confirm the aggregate cash, cash equivalents, and marketable securities of Creative, Ontogeny, and Reprogenesis immediately post-merger to validate the "end of 2001" runway claim.
- IPR&D Valuation: Review the independent appraisals used to value the $294.8 million in IPR&D assets, as these will result in a massive non-cash charge in the next quarter.
- Goodwill Allocation: Verify the final allocation of the $123.3 million in goodwill and the amortization schedule for other intangibles.
- Transaction Costs: Confirm the final transaction costs included in the purchase price estimates, as these affect the final equity structure.